JP2011500582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500582A5 JP2011500582A5 JP2010529007A JP2010529007A JP2011500582A5 JP 2011500582 A5 JP2011500582 A5 JP 2011500582A5 JP 2010529007 A JP2010529007 A JP 2010529007A JP 2010529007 A JP2010529007 A JP 2010529007A JP 2011500582 A5 JP2011500582 A5 JP 2011500582A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- composition according
- treatment cycle
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97959407P | 2007-10-12 | 2007-10-12 | |
| US60/979,594 | 2007-10-12 | ||
| US2766808P | 2008-02-11 | 2008-02-11 | |
| US61/027,668 | 2008-02-11 | ||
| US4064108P | 2008-03-28 | 2008-03-28 | |
| US61/040,641 | 2008-03-28 | ||
| PCT/US2008/079224 WO2009048967A1 (en) | 2007-10-12 | 2008-10-08 | Combination therapy with antibody-drug conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500582A JP2011500582A (ja) | 2011-01-06 |
| JP2011500582A5 true JP2011500582A5 (https=) | 2011-11-10 |
| JP5485897B2 JP5485897B2 (ja) | 2014-05-07 |
Family
ID=40549535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010529007A Expired - Fee Related JP5485897B2 (ja) | 2007-10-12 | 2008-10-08 | 抗体−薬物複合体の併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8263083B2 (https=) |
| EP (1) | EP2211885B1 (https=) |
| JP (1) | JP5485897B2 (https=) |
| KR (1) | KR101641345B1 (https=) |
| CN (1) | CN101969970B (https=) |
| AU (1) | AU2008310908B2 (https=) |
| CA (1) | CA2699090C (https=) |
| EA (1) | EA020696B1 (https=) |
| IL (1) | IL204851A (https=) |
| MX (1) | MX2010003977A (https=) |
| NZ (1) | NZ584552A (https=) |
| WO (1) | WO2009048967A1 (https=) |
| ZA (1) | ZA201002428B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| DK2474557T3 (da) | 2007-07-16 | 2014-11-10 | Genentech Inc | Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse |
| NZ583318A (en) | 2007-07-16 | 2012-07-27 | Genentech Inc | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| CN101969970B (zh) | 2007-10-12 | 2014-10-15 | 西雅图基因公司 | 用抗体-药物偶联物联合治疗 |
| SG187517A1 (en) | 2008-01-31 | 2013-02-28 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
| CA3159253A1 (en) | 2009-01-09 | 2010-07-15 | Seagen Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| US8758758B1 (en) * | 2010-01-08 | 2014-06-24 | Seattle Genetics, Inc. | Post-relapse treatment of CD30 expressing lymphomas |
| AU2011213609B2 (en) * | 2010-02-08 | 2016-11-03 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 161P2F10B proteins |
| AU2011316917B2 (en) * | 2010-10-22 | 2016-02-25 | Seagen Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway |
| CA2848520C (en) | 2011-09-29 | 2019-11-26 | Seattle Genetics, Inc. | Intact mass determination of protein conjugated agent compounds |
| WO2013055993A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| MY168297A (en) | 2011-11-17 | 2018-10-23 | Pfizer | Cytotoxic Peptides and Antibody Drug Conjugates Thereof |
| EP3575794A1 (en) * | 2012-02-10 | 2019-12-04 | Seattle Genetics, Inc. | Detection and treatment of cd30+ cancers |
| HK1214282A1 (zh) | 2012-11-07 | 2016-07-22 | 辉瑞公司 | 抗-notch3抗体及抗体-药物缀合物 |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| EP3160513B1 (en) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| PT3262071T (pt) | 2014-09-23 | 2020-06-16 | H Hoffnabb La Roche Ag | Métodos de utilização de imunoconjugados anti-cd79b |
| AU2015352545B2 (en) | 2014-11-25 | 2020-10-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| EP3694559A2 (en) * | 2017-10-11 | 2020-08-19 | Seattle Genetics, Inc. | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy |
| MA50369A (fr) * | 2017-10-13 | 2020-08-19 | Seattle Genetics Inc | Modulation de la réponse immunitaire à l'aide de conjugués anticorps-médicament |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| CA3094313A1 (en) * | 2018-04-06 | 2019-10-10 | Seattle Genetics, Inc. | Camptothecin peptide conjugates |
| WO2019217455A1 (en) | 2018-05-07 | 2019-11-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| TWI861039B (zh) | 2018-12-21 | 2024-11-11 | 瑞士商赫孚孟拉羅股份公司 | 靶向腫瘤之促效cd28抗原結合分子 |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| AU2020356955A1 (en) * | 2019-10-04 | 2022-04-14 | Seagen Inc. | Camptothecin peptide conjugates |
| MX2022009389A (es) * | 2020-01-31 | 2022-10-13 | Seagen Inc | Conjugados de farmaco-anticuerpo anti-cd30 y su uso para el tratamiento de linfoma no hodgkin. |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| CN119490595B (zh) * | 2023-08-15 | 2025-11-18 | 东莞市朋志生物科技有限公司 | 一种抗免疫球蛋白e的抗体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5165922A (en) * | 1990-05-22 | 1992-11-24 | Bristol-Myers Squibb Company | Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy |
| US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| US20070134243A1 (en) * | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
| HUE035853T2 (en) * | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| WO2007044616A2 (en) * | 2005-10-06 | 2007-04-19 | Xencor, Inc. | Optimized anti-cd30 antibodies |
| US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| US8257706B2 (en) * | 2006-08-25 | 2012-09-04 | Seattle Genetics, Inc. | CD30 binding agents and uses thereof |
| WO2008103916A2 (en) | 2007-02-23 | 2008-08-28 | The Trustees Of Columbia Univeristy In The City Of New York | Compositions and methods for treating cancer or a neurotrophic disorder |
| CN101969970B (zh) | 2007-10-12 | 2014-10-15 | 西雅图基因公司 | 用抗体-药物偶联物联合治疗 |
-
2008
- 2008-10-08 CN CN200880111297.1A patent/CN101969970B/zh active Active
- 2008-10-08 EA EA201070463A patent/EA020696B1/ru unknown
- 2008-10-08 US US12/681,599 patent/US8263083B2/en active Active
- 2008-10-08 EP EP08837451.7A patent/EP2211885B1/en active Active
- 2008-10-08 KR KR1020107008660A patent/KR101641345B1/ko active Active
- 2008-10-08 CA CA2699090A patent/CA2699090C/en active Active
- 2008-10-08 WO PCT/US2008/079224 patent/WO2009048967A1/en not_active Ceased
- 2008-10-08 JP JP2010529007A patent/JP5485897B2/ja not_active Expired - Fee Related
- 2008-10-08 MX MX2010003977A patent/MX2010003977A/es active IP Right Grant
- 2008-10-08 NZ NZ584552A patent/NZ584552A/en unknown
- 2008-10-08 AU AU2008310908A patent/AU2008310908B2/en not_active Ceased
-
2010
- 2010-04-06 IL IL204851A patent/IL204851A/en active IP Right Grant
- 2010-04-07 ZA ZA2010/02428A patent/ZA201002428B/en unknown
-
2012
- 2012-08-13 US US13/571,313 patent/US8470329B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500582A5 (https=) | ||
| Mahalingaiah et al. | Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates | |
| Hedrich et al. | Antibody–drug conjugates: pharmacokinetic/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned | |
| TWI804499B (zh) | Ror1抗體免疫接合物 | |
| Trail et al. | Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design | |
| Mack et al. | The next generation of antibody drug conjugates | |
| JP6297550B2 (ja) | 抗ｃｄ７９ｂ抗体を含む免疫複合体 | |
| Hassan et al. | New life for immunotoxin cancer therapy | |
| NZ707543A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| Drachman et al. | Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer | |
| JP2011508738A5 (https=) | ||
| WO2004050705A3 (en) | Complexes of receptors | |
| WO2007134037A3 (en) | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments | |
| JP2016183182A5 (https=) | ||
| DE602005026789D1 (de) | Le | |
| JP2017537893A5 (https=) | ||
| NZ707534A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| JP2015531750A5 (https=) | ||
| EP2393854A2 (en) | Nanoscale platinum compounds and methods of use thereof | |
| WO2015057250A1 (en) | Combination therapies with psma ligand conjugates | |
| JP2021505661A5 (https=) | ||
| EP2800586A1 (en) | Ligand-targeted molecules and methods thereof | |
| JP2019503387A5 (https=) | ||
| JP2006265245A5 (https=) | ||
| Vassilakopoulos et al. | Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years |